Cancer Fighters Certificate
The fight against cancer involves a double revolution: medical and financial. Driven by innovations such as immunotherapies and RNA vaccines, it is redefining treatments and fuelling significant economic growth. The oncology market was worth $201.8 billion in 2023 and is projected to be worth $668.26 billion by 2034. This growth is embodied by Keytruda, a leading cancer immunotherapy treatment, which has become the world's best-selling drug. A transformation is underway, benefiting patients and investors.
ISIN: CH1345423755
The Cancer Fighters certificate offers a unique opportunity to invest in the future of oncology. This portfolio is made up of pioneering companies in targeted therapies, immunotherapies, early detection and messenger RNA vaccines, revolutionising healthcare and diagnostics. By supporting these key players, investors will play their part in achieving a major breakthrough in the fight against cancer, while capitalising on a fast-growing industry that lies at the heart of the world's public health challenges.
Increased growth potential
Broad diversification
Professionally and actively managed
Traded on the SIX Swiss Exchange
CHF 9.- flat transaction costs (excluding stock exchange and real time fees)
Subscribe to our Newsletter to receive market news, trade ideas & new themes